Neurotoxic Emergencies

Neurologic Clinics

Volumn 29, Issue 3, 2011, Pages 539-563

  Barry, J Dave ^a,b   Wills, Brandon K ^c,d,e  

^a NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e Virginia Poison Center   (United States)

Author keywords

Emergency; Neurology; Overdose; Poisoning; Toxicology

Indexed keywords

ACTIVATED CARBON; ALCOHOL; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BICARBONATE; CARBAMAZEPINE; CITALOPRAM; COCAINE; DEXTROPROPOXYPHENE; ESCITALOPRAM; ISONIAZID; LAMOTRIGINE; LITHIUM; MACROGOL; METHYLXANTHINE; NEUROTRANSMITTER; PETHIDINE; PHENYTOIN; PROXYPHYLLINE; QUININE; SALICYLIC ACID; THEOPHYLLINE; TIAGABINE; TOPIRAMATE; TRAMADOL; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; AGITATION; ALKALINIZATION; ANXIETY DISORDER; APPARENT LIFE THREATENING EVENT; BOTULISM; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DEPRESSION; CIGUATERA; COMA; CONFUSION; DEPRESSION; DIAPHORESIS; DRUG ABUSE; DRUG INTOXICATION; DRUG OVERDOSE; EMERGENCY CARE; EPILEPTIC STATE; FLUSHING; GRAND MAL SEIZURE; HALLUCINATION; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERREFLEXIA; HYPERTENSION; HYPERTHERMIA; HYPOTENSION; LACTIC ACIDOSIS; LETHARGY; MENTAL HEALTH; METABOLISM; MOLECULAR MECHANICS; MUSCLE RIGIDITY; MYDRIASIS; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; PARALYSIS; PRIORITY JOURNAL; PUFFER FISH; QT PROLONGATION; REVIEW; RHABDOMYOLYSIS; SEIZURE; SHELLFISH POISONING; SHIVERING; SIDE EFFECT; STOMACH LAVAGE; TACHYCARDIA; TACHYPNEA; TICK BITE; TREMOR;

EMERGENCIES; HUMANS; NEUROTOXICITY SYNDROMES; SEIZURES;

EID: 79960781497     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2011.05.006     Document Type: Review

References (180)

1. Stedman's medical dictionary 1990, Williams & Wilkins, Baltimore(MD). 25th edition.
2. Thundiyil J.G., Rowley F., Papa L., et al. Risk factors for complications of drug-induced seizures. J Med Toxicol 2011, 7:16-23.
3. Thundiyil J.G., Kearney T.E., Olson K.R. Evolving epidemiology of drug-induced seizures reported to a poison control center system. J Toxicol Clin Toxicol 2004, 42(5):730.
4. Olson K.R., Kearney T.E., Dyer J.E., et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1994, 12(3):392-395.
5. Sharma A.N., Hoffman R.J. Toxin-related seizures. Emerg Med Clin North Am 2011, 29(1):125-139.
6. Woolf A.D., Erdman A.R., Nelson L.S., et al. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007, 45(3):203-233.
7. Bebarta V.S., Maddry J., Borys D.J., et al. Incidence of tricyclic antidepressant-like complications after cyclobenzaprine overdose. Am J Emerg Med 2010, [Epub ahead of print].
8. Bradberry S.M., Thanacoody H.K., Watt B.E., et al. Management of the cardiovascular complications of tricyclic antidepressant poisoning: role of sodium bicarbonate. Toxicol Rev 2005, 24(3):195-204.
9. Dhillon S., Yang L.P., Curran M.P. Spotlight on bupropion in major depressive disorder. CNS Drugs 2008, 22(7):613-617.
10. Starr P., Klein-Schwartz W., Spiller H., et al. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med 2009, 27(8):911-915.
11. Nelson L.S., Erdman A.R., Booze L.L., et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007, 45(4):315-332.
12. Waring W.S., Gray J.A., Graham A. Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol 2008, 66(6):861-865.
13. Hayes B.D., Klein-Schwartz W., Clark R.F., et al. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 2010, 39(1):44-48.
14. Yilmaz Z., Ceschi A., Rauber-Luthy C., et al. Escitalopram causes fewer seizures in human overdose than citalopram. Clin Toxicol (Phila) 2010, 48(3):207-212.
15. Perucca E., Gram L., Avanzini G., et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998, 39(1):5-17.
16. Spiller H.A., Carlisle R.D. Status epilepticus after massive carbamazepine overdose. J Toxicol Clin Toxicol 2002, 40(1):81-90.
17. Sullivan J.B., Rumack B.H., Peterson R.G. Acute carbamazepine toxicity resulting from overdose. Neurology 1981, 31(5):621-624.
18. Guerrini R., Belmonte A., Parmeggiani L., et al. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999, 21(6):420-424.
19. Hasan M., Lerman-Sagie T., Lev D., et al. Recurrent absence status epilepticus (spike-and-wave stupor) associated with lamotrigine therapy. J Child Neurol 2006, 21(9):807-809.
20. Trinka E., Dilitz E., Unterberger I., et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002, 249(10):1417-1422.
21. Dinnerstein E., Jobst B.C., Williamson P.D. Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Arch Neurol 2007, 64(9):1344-1346.
22. Thundiyil J.G., Anderson I.B., Stewart P.J., et al. Lamotrigine-induced seizures in a child: case report and literature review. Clin Toxicol (Phila) 2007, 45(2):169-172.
23. Anand J.S., Chodorowski Z., Wisniewski M. Seizures induced by topiramate overdose. Clin Toxicol (Phila) 2007, 45(2):197.
24. Wisniewski M., Lukasik-Glebocka M., Anand J.S. Acute topiramate overdose-clinical manifestations. Clin Toxicol (Phila) 2009, 47(4):317-320.
25. Jette N., Cappell J., VanPassel L., et al. Tiagabine-induced nonconvulsive status epilepticus in an adolescent without epilepsy. Neurology 2006, 67(8):1514-1515.
26. Kazzi Z.N., Jones C.C., Morgan B.W. Seizures in a pediatric patient with a tiagabine overdose. J Med Toxicol 2006, 2(4):160-162.
27. Ostrovskiy D., Spanaki M.V., Morris G.L. Tiagabine overdose can induce convulsive status epilepticus. Epilepsia 2002, 43(7):773-774.
28. Devlin R.J., Henry J.A. Clinical review: major consequences of illicit drug consumption. Crit Care 2008, 12(1):202.
29. Paloucek F.P., Rodvold K.A. Evaluation of theophylline overdoses and toxicities. Ann Emerg Med 1988, 17(2):135-144.
30. Shanti C.M., Lucas C.E. Cocaine and the critical care challenge. Crit Care Med 2003, 31(6):1851-1859.
31. Catravas J.D., Waters I.W. Acute cocaine intoxication in the conscious dog: studies on the mechanism of lethality. J Pharmacol Exp Ther 1981, 217(2):350-356.
32. Gill J.R., Hayes J.A., deSouza I.S., et al. Ecstasy (MDMA) deaths in New York City: a case series and review of the literature. J Forensic Sci 2002, 47(1):121-126.
33. Kojima T., Une I., Yashiki M., et al. A fatal methamphetamine poisoning associated with hyperpyrexia. Forensic Sci Int 1984, 24(1):87-93.
34. Patel M.M., Belson M.G., Longwater A.B., et al. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 2005, 29(4):451-454.
35. Young G.P., Rores C., Murphy C., et al. Intravenous phenobarbital for alcohol withdrawal and convulsions. Ann Emerg Med 1987, 16(8):847-850.
36. Hyser C.L., Drake M.E. Status epilepticus after baclofen withdrawal. J Natl Med Assoc 1984, 76(5). 533, 537-8.
37. Kofler M., Arturo Leis A. Prolonged seizure activity after baclofen withdrawal. Neurology 1992, 42(3 Pt 1):697-698.
38. Peng C.T., Ger J., Yang C.C., et al. Prolonged severe withdrawal symptoms after acute-on-chronic baclofen overdose. J Toxicol Clin Toxicol 1998, 36(4):359-363.
39. Brust J.C. Seizures and substance abuse: treatment considerations. Neurology 2006, 67(12 Suppl 4):S45-S48.
40. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43(13):879-923.
41. Jovanovic-Cupic V., Martinovic Z., Nesic N. Seizures associated with intoxication and abuse of tramadol. Clin Toxicol (Phila) 2006, 44(2):143-146.
42. Shadnia S., Soltaninejad K., Heydari K., et al. Tramadol intoxication: a review of 114 cases. Hum Exp Toxicol 2008, 27(3):201-205.
43. Spiller H.A., Gorman S.E., Villalobos D., et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol 1997, 35(4):361-364.
44. Afshari R., Ghooshkhanehee H. Tramadol overdose induced seizure, dramatic rise of CPK and acute renal failure. J Pak Med Assoc 2009, 59(3):178.
45. Sansone R.A., Sansone L.A. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants. Psychiatry (Edgmont) 2009, 6(4):17-21.
46. Lawson A.A., Northridge D.B. Dextropropoxyphene overdose. Epidemiology, clinical presentation and management. Med Toxicol Adverse Drug Exp 1987, 2(6):430-444.
47. Sloth Madsen P., Strom J., Reiz S., et al. Acute propoxyphene self-poisoning in 222 consecutive patients. Acta Anaesthesiol Scand 1984, 28(6):661-665.
48. Stork C.M., Redd J.T., Fine K., et al. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate-a case report. J Toxicol Clin Toxicol 1995, 33(2):179-183.
49. Ramirez J., Innocenti F., Schuetz E.G., et al. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 2004, 32(9):930-936.
50. Seifert C.F., Kennedy S. Meperidine is alive and well in the new millennium: evaluation of meperidine usage patterns and frequency of adverse drug reactions. Pharmacotherapy 2004, 24(6):776-783.
51. Maw G., Aitken P. Isoniazid overdose: a case series, literature review and survey of antidote availability. Clin Drug Investig 2003, 23(7):479-485.
52. Vale J.A., Kulig K. Position paper: gastric lavage. J Toxicol Clin Toxicol 2004, 42(7):933-943.
53. Chyka P.A., Seger D., Krenzelok E.P., et al. Position paper: single-dose activated charcoal. Clin Toxicol (Phila) 2005, 43(2):61-87.
54. Position paper: whole bowel irrigation. J Toxicol Clin Toxicol 2004, 42(6):843-854.
55. Bryant S.M., Weiselberg R., Metz J., et al. Should no bowel irrigation be a higher priority than whole bowel irrigation in the treatment of sustained-release ingestions?. Clin Toxicol (Phila) 2008, 47(7):638. [abstract].
56. Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999, 37(6):731-751.
57. Proudfoot A.T., Krenzelok E.P., Vale J.A. Position paper on urine alkalinization. J Toxicol Clin Toxicol 2004, 42(1):1-26.
58. Wills B., Erickson T. Chemically induced seizures. Clin Lab Med 2006, 26(1):185-209. ix.
59. Nolop K.B., Natow A. Unprecedented sedative requirements during delirium tremens. Crit Care Med 1985, 13(4):246-247.
60. Woo E., Greenblatt D.J. Massive benzodiazepine requirements during acute alcohol withdrawal. Am J Psychiatry 1979, 136(6):821-823.
61. Coomes T.R., Smith S.W. Successful use of propofol in refractory delirium tremens. Ann Emerg Med 1997, 30(6):825-828.
62. McCowan C., Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med 2000, 28(6):1781-1784.
63. Claassen J., Hirsch L.J., Emerson R.G., et al. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002, 43(2):146-153.
64. Rossetti A.O., Reichhart M.D., Schaller M.D., et al. Propofol treatment of refractory status epilepticus: a study of 31 episodes. Epilepsia 2004, 45(7):757-763.
65. Shah A.S., Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures?. Clin Toxicol (Phila) 2010, 48(8):800-805.
66. Bazil C.W., Pedley T.A. Clinical pharmacology of antiepileptic drugs. Clin Neuropharmacol 2003, 26(1):38-52.
67. Tutka P., Mroz T., Klucha K., et al. Bupropion-induced convulsions: preclinical evaluation of antiepileptic drugs. Epilepsy Res 2005, 64(1/2):13-22.
68. Brent J., Vo N., Kulig K., et al. Reversal of prolonged isoniazid-induced coma by pyridoxine. Arch Intern Med 1990, 150(8):1751-1753.
69. Shannon M., McElroy E.A., Liebelt E.L. Toxic seizures in children: case scenarios and treatment strategies. Pediatr Emerg Care 2003, 19(3):206-210.
70. Uusi-Oukari M., Korpi E.R. Regulation of GABA(A) receptor subunit expression by pharmacological agents. Pharmacol Rev 2010, 62(1):97-135.
71. Curry S.C., Mills K.C., Ruha A.M., et al. Neurotransmitters and neuromodulators. Goldfrank's toxicologic emergencies 2011, 189-220. McGraw-Hill Companies, New York. 9th edition. L.S. Nelson, N.A. Lewin, M.A. Howland (Eds.).
72. Bormann J. The 'ABC' of GABA receptors. Trends Pharmacol Sci 2000, 21(1):16-19.
73. Akhtar J., Rittenberger J.C. Clinical neurotoxicology. Haddad and Winchester's clinical management of poisoning and drug overdose 2007, 191-207. Elsevier, Philadelphia. 4th edition. M.W. Shannon, S.W. Borron, M.J. Burns (Eds.).
74. Korpi E.R., Mattila M.J., Wisden W., et al. GABA(A)-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 1997, 29(4):275-282.
75. A/benzodiazepine receptor heterogeneity: neurophysiological implications. Neuropharmacology 1995, 34(3):245-254.
76. Olsen R.W., Li G.D. GABA(A) receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anaesth 2011, 58(2):206-215.
77. Halpern J.H. Hallucinogens and dissociative agents naturally growing in the United States. Pharmacol Ther 2004, 102(2):131-138.
78. Shirley K.W., Kothare S., Piatt J.H., et al. Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care 2006, 22(4):258-261.
79. Chateauvieux S., Morceau F., Dicato M., et al. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010, 2010:479364.
80. Mesdjian E., Ciesielski L., Valli M., et al. Sodium valproate: kinetic profile and effects on GABA levels in various brain areas of the rat. Prog Neuropsychopharmacol Biol Psychiatry 1982, 6(3):223-233.
81. Urban M.O., Ren K., Park K.T., et al. Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action. J Pharmacol Exp Ther 2005, 313(3):1209-1216.
82. Sarup A., Larsson O.M., Schousboe A. GABA transporters and GABA-transaminase as drug targets. Curr Drug Targets CNS Neurol Disord 2003, 2(4):269-277.
83. McNamara J.O. Pharmacotherapy of the epilepsies. Goodman & Gillman's the pharmacological basis of therapeutics 2005, 501-525. Mc-Graw Hill, New York. 11th edition. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
84. Ngo A.S., Anthony C.R., Samuel M., et al. Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department?. Resuscitation 2007, 74(1):27-37.
85. Seger D.L. Flumazenil-treatment or toxin. J Toxicol Clin Toxicol 2004, 42(2):209-216.
86. Nemeth Z., Kun B., Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010, 24(9):1281-1287.
87. Carter L.P., Koek W., France C.P. Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther 2009, 121(1):100-114.
88. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997, 51(3):337-361.
89. Wong C.G., Gibson K.M., Snead O.C. From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 2004, 25(1):29-34.
90. Li J., Stokes S.A., Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998, 31(6):729-736.
91. Liechti M.E., Kunz I., Greminger P., et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006, 81(3):323-326.
92. Zvosec D.L., Smith S.W., McCutcheon J.R., et al. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001, 344(2):87-94.
93. Shannon M., Quang L.S. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 2000, 16(6):435-440.
94. Van Sassenbroeck D.K., De Neve N., De Paepe P., et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007, 45(5):533-538.
95. Farmer B.M. Gamma-hydroxybutyric acid. Goldfrank's toxicologic emergencies 2011, 1151-1156. McGraw Hill, New York. 9th edition. L.S. Nelson, N.A. Lewin, M.A. Howland (Eds.).
96. Quang L.S. GHB and related compounds. Haddad and Winchester's clinical management of poisoning and drug overdose 2007, 803-823. Elsevier, Philadelphia. 4th edition. M.W. Shannon, S.W. Borron, M.J. Burns (Eds.).
97. LeTourneau J.L., Hagg D.S., Smith S.M. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008, 8(3):430-433.
98. Trescot A.M., Datta S., Lee M., et al. Opioid pharmacology. Pain Physician 2008, 11(Suppl 2):S133-S153.
99. Dietis N., Guerrini R., Calo G., et al. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br J Anaesth 2009, 103(1):38-49.
100. Meehan T.J., Bryant S.M., Aks S.E. Drugs of abuse: the highs and lows of altered mental states in the emergency department. Emerg Med Clin North Am 2010, 28(3):663-682.
101. Dahan A., Aarts L., Smith T.W. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010, 112(1):226-238.
102. Vardakou I., Pistos C., Spiliopoulou C. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010, 197(3):157-162.
103. Schneir A.B., Cullen J., Ly B.T. "Spice" girls: synthetic cannabinoid intoxication. J Emerg Med 2011, 40(3):296-299.
104. Elkashef A., Vocci F., Huestis M., et al. Marijuana neurobiology and treatment. Subst Abus 2008, 29(3):17-29.
105. Felder C.C., Glass M. Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol 1998, 38:179-200.
106. McPartland J.M. The endocannabinoid system: an osteopathic perspective. J Am Osteopath Assoc 2008, 108(10):586-600.
107. Ashton C.H. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001, 178:101-106.
108. Iversen L. Cannabis and the brain. Brain 2003, 126(Pt 6):1252-1270.
109. Campbell F.A., Tramer M.R., Carroll D., et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001, 323(7303):13-16.
110. Johns A. Psychiatric effects of cannabis. Br J Psychiatry 2001, 178:116-122.
111. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend 2011, [Epub ahead of print].
112. Zimmermann U.S., Winkelmann P.R., Pilhatsch M., et al. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold" Dtsch Arztebl Int 2009, 106(27):464-467.
113. Insel P.A. Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 1996, 334(9):580-585.
114. Beaulieu J.M., Gainetdinov R.R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 2011, 63(1):182-217.
115. Millan M.J., Marin P., Bockaert J., et al. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008, 29(9):454-464.
116. Green A.R., Mechan A.O., Elliott J.M., et al. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 2003, 55(3):463-508.
117. Sulzer D., Sonders M.S., Poulsen N.W., et al. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75(6):406-433.
118. Aghajanian G.K., Marek G.J. Serotonin and hallucinogens. Neuropsychopharmacology 1999, 21(Suppl 2):16S-23S.
119. DEA Methylenedioxypyrovalerone (MDPV). Drugs and chemicals of concern Available at:, Accessed March 26, 2011. http://www.deadiversion.usdoj.gov/drugs_concern/mdpv.pdf.
120. ACMD Consideration of the cathinones. Advisory council on the misuse of drugs Available at:, Accessed March 26, 2011. http://www.namsdl.org/documents/ACMDCathinonesReport.pdf.
121. Schwartz B.G., Rezkalla S., Kloner R.A. Cardiovascular effects of cocaine. Circulation 2010, 122(24):2558-2569.
122. Smith J.A., Mo Q., Guo H., et al. Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens. Brain Res 1995, 683(2):264-269.
123. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 8: advanced challenges in resuscitation: section 2: toxicology in ECC. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000, 102(Suppl 8):I223-I228.
124. Albertson T.E., Dawson A., de Latorre F., et al. TOX-ACLS: toxicologic-oriented advanced cardiac life support. Ann Emerg Med 2001, 37(Suppl 4):S78-S90.
125. Lange R.A., Cigarroa R.G., Flores E.D., et al. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med 1990, 112(12):897-903.
126. Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med 2005, 352(11):1112-1120.
127. Juurlink D.N. Antipsychotics. Goldfrank's toxicologic emergencies 2011, 1103-1115. McGraw Hill, New York. 9th edition. L.S. Nelson, N.A. Lewin, M.A. Howland (Eds.).
128. Levine M., Burns M.J. Antipsychotic agents. Haddad and Winchester's clinical management of poisoning and drug overdose 2007, 703-720. Elsevier, Philadelphia. 4th edition. M.W. Shannon, S.W. Borron, M.J. Burns (Eds.).
129. Adnet P., Lestavel P., Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000, 85(1):129-135.
130. Strawn J.R., Keck P.E., Caroff S.N. Neuroleptic malignant syndrome. Am J Psychiatry 2007, 164(6):870-876.
131. Reulbach U., Dutsch C., Biermann T., et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007, 11(1):R4.
132. Ener R.A., Meglathery S.B., Van Decker W.A., et al. Serotonin syndrome and other serotonergic disorders. Pain Med 2003, 4(1):63-74.
133. Birmes P., Coppin D., Schmitt L., et al. Serotonin syndrome: a brief review. CMAJ 2003, 168(11):1439-1442.
134. Isbister G.K., Buckley N.A. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005, 28(5):205-214.
135. Radomski J.W., Dursun S.M., Reveley M.A., et al. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000, 55(3):218-224.
136. Javitt D.C. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004, 9(11):984-997. 979.
137. Kew J.N., Kemp J.A. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005, 179(1):4-29.
138. Mori H., Mishina M. Structure and function of the NMDA receptor channel. Neuropharmacology 1995, 34(10):1219-1237.
139. Weiner A.L., Vieira L., McKay C.A., et al. Ketamine abusers presenting to the emergency department: a case series. J Emerg Med 2000, 18(4):447-451.
140. Bahn E.L., Holt K.R. Procedural sedation and analgesia: a review and new concepts. Emerg Med Clin North Am 2005, 23(2):503-517.
141. Reich D.L., Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989, 36(2):186-197.
142. Liang I.E., Boyer E.W. Dissociative agents: phencyclidine, ketamine and dextromethorphan. Haddad and Winchester's clinical management of poisoning and drug overdose 2007, 773-779. Elsevier, Philadelphia. 4th edition. M.W. Shannon, S.W. Borron, M.J. Burns (Eds.).
143. Jeffery B., Barlow T., Moizer K., et al. Amnesic shellfish poison. Food Chem Toxicol 2004, 42(4):545-557.
144. Lefebvre K.A., Robertson A. Domoic acid and human exposure risks: a review. Toxicon 2010, 56(2):218-230.
145. Sidell F.R., Borak J. Chemical warfare agents: II. Nerve agents. Ann Emerg Med 1992, 21(7):865-871.
146. White J., Warrell D., Eddleston M., et al. Clinical toxinology-where are we now?. J Toxicol Clin Toxicol 2003, 41(3):263-276.
147. Khandelwal G., Katz K.D., Brooks D.E., et al. Naja Kaouthia: two cases of Asiatic cobra envenomations. J Emerg Med 2007, 32(2):171-174.
148. Prasarnpun S., Walsh J., Awad S.S., et al. Envenoming bites by kraits: the biological basis of treatment-resistant neuromuscular paralysis. Brain 2005, 128(Pt 12):2987-2996.
149. Rowan E.G. What does beta-bungarotoxin do at the neuromuscular junction?. Toxicon 2001, 39(1):107-118.
150. Sanmuganathan P.S. Myasthenic syndrome of snake envenomation: a clinical and neurophysiological study. Postgrad Med J 1998, 74(876):596-599.
151. Edlow J.A., McGillicuddy D.C. Tick paralysis. Infect Dis Clin North Am 2008, 22(3):397-413. vii.
152. Felz M.W., Smith C.D., Swift T.R. A six-year-old girl with tick paralysis. N Engl J Med 2000, 342(2):90-94.
153. Greenstein P. Tick paralysis. Med Clin North Am 2002, 86(2):441-446.
154. Humeau Y., Doussau F., Grant N.J., et al. How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie 2000, 82(5):427-446.
155. Klein A.W. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg 2001, 20(2):109-120.
156. Caleo M., Schiavo G. Central effects of tetanus and botulinum neurotoxins. Toxicon 2009, 54(5):593-599.
157. Goonetilleke A., Harris J.B. Clostridial neurotoxins. J Neurol Neurosurg Psychiatry 2004, 75(Suppl 3):iii35-iii39.
158. Lawrence D.T., Dobmeier S.G., Bechtel L.K., et al. Food poisoning. Emerg Med Clin North Am 2007, 25(2):357-373. [abstract ix].
159. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285(8):1059-1070.
160. Handel C.C., Izquierdo L.A., Curet L.B. Black widow spider (Latrodectus mactans) bite during pregnancy. West J Med 1994, 160(3):261-262.
161. Ushkaryov Y.A., Volynski K.E., Ashton A.C. The multiple actions of black widow spider toxins and their selective use in neurosecretion studies. Toxicon 2004, 43(5):527-542.
162. Vetter R.S., Isbister G.K. Medical aspects of spider bites. Annu Rev Entomol 2008, 53:409-429.
163. Graudins A. Spiders. Haddad and Winchester's clinical management of poisoning and drug overdose 2007, 433-439. Elsevier, Philadelphia. 4th edition. M.W. Shannon, S.W. Borron, M.J. Burns (Eds.).
164. Hahn I. Arthropods. Goldfrank's toxicologic emergencies 2011, 1561-1581. McGraw Hill, New York. 9th edition. L.S. Nelson, N.A. Lewin, M.A. Howland (Eds.).
165. Daly F.F., Hill R.E., Bogdan G.M., et al. Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom. J Toxicol Clin Toxicol 2001, 39(2):119-123.
166. Isbister G.K., Graudins A., White J., et al. Antivenom treatment in arachnidism. J Toxicol Clin Toxicol 2003, 41(3):291-300.
167. Webb T.I., Lynch J.W. Molecular pharmacology of the glycine receptor chloride channel. Curr Pharm Des 2007, 13(23):2350-2367.
168. Makarovsky I., Markel G., Hoffman A., et al. Strychnine-a killer from the past. Isr Med Assoc J 2008, 10(2):142-145.
169. Chan T.Y. Herbal medicine causing likely strychnine poisoning. Hum Exp Toxicol 2002, 21(8):467-468.
170. Wood D., Webster E., Martinez D., et al. Case report: survival after deliberate strychnine self-poisoning, with toxicokinetic data. Crit Care 2002, 6(5):456-459.
171. Afshar M., Raju M., Ansell D., et al. Narrative review: tetanus-a health threat after natural disasters in developing countries. Ann Intern Med 2011, 154(5):329-335.
172. Wang S.Y., Wang G.K. Voltage-gated sodium channels as primary targets of diverse lipid-soluble neurotoxins. Cell Signal 2003, 15(2):151-159.
173. Wang D.Z. Neurotoxins from marine dinoflagellates: a brief review. Mar Drugs 2008, 6(2):349-371.
174. Purcell C.E., Capra M.F., Cameron J. Action of mannitol in ciguatoxin-intoxicated rats. Toxicon 1999, 37(1):67-76.
175. Sobel J., Painter J. Illnesses caused by marine toxins. Clin Infect Dis 2005, 41(9):1290-1296.
176. Schnorf H., Taurarii M., Cundy T. Ciguatera fish poisoning: a double-blind randomized trial of mannitol therapy. Neurology 2002, 58(6):873-880.
177. Isbister G.K. Marine envenomation and poisoning. Medical toxicology 2004, 1621-1644. Lippincott Williams & Wilkins, Philadelphia. 3rd edition. R.C. Dart (Ed.).
178. Bosmans F., Maertens C., Verdonck F., et al. The poison dart frog's batrachotoxin modulates Nav1.8. FEBS Lett 2004, 577(1-2):245-248.
179. Araoz R., Molgo J., Tandeau de Marsac N. Neurotoxic cyanobacterial toxins. Toxicon 2010, 56(5):813-828.
180. How C.K., Chern C.H., Huang Y.C., et al. Tetrodotoxin poisoning. Am J Emerg Med 2003, 21(1):51-54.